EBIO Eleven Biotherapeutics, Inc.

1.48
+0.15  (11%)
Previous Close 1.33
Open 1.34
Price To book 1.00
Market Cap 22.78M
Shares 15,393,000
Volume 849,495
Short Ratio 6.68
Av. Daily Volume 449,630

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Phase 1/2a trial to be initiated 2H 2017.
Proxinium
Squamous cell carcinoma of the head and neck - cancer
Phase 3 enrollment to be completed 2H 2017, with top-line data due 2018.
Vicinium
Non-muscle invasive bladder cancer (NMIBC)
Phase 3 topline data showed endpoints not met mid May 2015
Isunakinra (EBI-005)
Moderate to severe dry eye disease

Latest News

  1. Eleven Biotherapeutics Continues Expansion of Clinical Development Team with Appointment of David Brooks, M.D., Ph.D., to Senior Vice President, Clinical Development
  2. ETFs with exposure to Eleven Biotherapeutics, Inc. : May 15, 2017
  3. Eleven Biotherapeutics, Inc. :EBIO-US: Earnings Analysis: Q1, 2017 By the Numbers : May 8, 2017
  4. Eleven Biotherapeutics Reports First Quarter 2017 Financial Results
  5. Investor Network: Eleven Biotherapeutics, Inc. to Host Earnings Call
  6. Eleven Biotherapeutics to Report First Quarter 2017 Financial Results on Thursday, May 4, 2017
  7. Eleven Biotherapeutics Presents New Preclinical Data at AACR Supporting the Potential of the Company’s Locally- and Systematically-Administered Drug Candidates
  8. Eleven Biotherapeutics, Inc. :EBIO-US: Earnings Analysis: Q4, 2016 By the Numbers : March 28, 2017
  9. Eleven Biotherapeutics to Present New Preclinical Data at the American Association for Cancer Research Annual Meeting 2017
  10. Eleven Biotherapeutics to Report Fourth Quarter and Full Year 2016 Financial Results on Friday, March 24, 2017
  11. Eleven Biotherapeutics to Present at Oppenheimer's 27th Annual Healthcare Conference
  12. Eleven Biotherapeutics to Present at Upcoming Investor Conferences in March
  13. Eleven Biotherapeutics to Present at the 2017 BIO CEO & Investor Conference
  14. Eleven Biotherapeutics, Inc. :EBIO-US: Earnings Analysis: Q3, 2016 By the Numbers : November 29, 2016
  15. Eleven Biotherapeutics Reports Third Quarter 2016 Financial Results
  16. Eleven Biotherapeutics to Report Third Quarter 2016 Financial Results on November 14, 2016
  17. ​Venture firm Third Rock raises $616M fund, names female partner
  18. 5 Companies That Destroyed Shareholders Last Week